145 related articles for article (PubMed ID: 22884950)
1. Synergism between clofarabine and decitabine through p53R2: a pharmacodynamic drug-drug interaction modeling.
Thudium KE; Ghoshal S; Fetterly GJ; Haese JP; Karpf AR; Wetzler M
Leuk Res; 2012 Nov; 36(11):1410-6. PubMed ID: 22884950
[TBL] [Abstract][Full Text] [Related]
2. p53-inducible ribonucleotide reductase (p53R2/RRM2B) is a DNA hypomethylation-independent decitabine gene target that correlates with clinical response in myelodysplastic syndrome/acute myelogenous leukemia.
Link PA; Baer MR; James SR; Jones DA; Karpf AR
Cancer Res; 2008 Nov; 68(22):9358-66. PubMed ID: 19010910
[TBL] [Abstract][Full Text] [Related]
3. A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia.
Chiarini F; Lonetti A; Teti G; Orsini E; Bressanin D; Cappellini A; Ricci F; Tazzari PL; Ognibene A; Falconi M; Pagliaro P; Iacobucci I; Martinelli G; Amadori S; McCubrey JA; Martelli AM
Oncotarget; 2012 Dec; 3(12):1615-28. PubMed ID: 23271044
[TBL] [Abstract][Full Text] [Related]
4. The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling.
Valdez BC; Li Y; Murray D; Champlin RE; Andersson BS
Biochem Pharmacol; 2011 Jan; 81(2):222-32. PubMed ID: 20933509
[TBL] [Abstract][Full Text] [Related]
5. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients.
Faderl S; Ravandi F; Huang X; Wang X; Jabbour E; Garcia-Manero G; Kadia T; Ferrajoli A; Konopleva M; Borthakur G; Burger J; Feliu J; Kantarjian HM
Cancer; 2012 Sep; 118(18):4471-7. PubMed ID: 22282348
[TBL] [Abstract][Full Text] [Related]
6. The potential of clofarabine in MLL-rearranged infant acute lymphoblastic leukaemia.
Stumpel DJ; Schneider P; Pieters R; Stam RW
Eur J Cancer; 2015 Sep; 51(14):2008-21. PubMed ID: 26188848
[TBL] [Abstract][Full Text] [Related]
7. Clofarabine ± fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS.
Andersson BS; Valdez BC; de Lima M; Wang X; Thall PF; Worth LL; Popat U; Madden T; Hosing C; Alousi A; Rondon G; Kebriaei P; Shpall EJ; Jones RB; Champlin RE
Biol Blood Marrow Transplant; 2011 Jun; 17(6):893-900. PubMed ID: 20946966
[TBL] [Abstract][Full Text] [Related]
8. Down-regulation of deoxycytidine kinase in human leukemic cell lines resistant to cladribine and clofarabine and increased ribonucleotide reductase activity contributes to fludarabine resistance.
Månsson E; Flordal E; Liliemark J; Spasokoukotskaja T; Elford H; Lagercrantz S; Eriksson S; Albertioni F
Biochem Pharmacol; 2003 Jan; 65(2):237-47. PubMed ID: 12504799
[TBL] [Abstract][Full Text] [Related]
9. The histone deacetylase inhibitor SAHA sensitizes acute myeloid leukemia cells to a combination of nucleoside analogs and the DNA-alkylating agent busulfan.
Song G; Valdez BC; Li Y; Dominguez JR; Corn P; Champlin RE; Andersson BS
Leuk Lymphoma; 2014 Jul; 55(7):1625-34. PubMed ID: 24144307
[TBL] [Abstract][Full Text] [Related]
10. Clofarabine: past, present, and future.
Kantarjian HM; Jeha S; Gandhi V; Wess M; Faderl S
Leuk Lymphoma; 2007 Oct; 48(10):1922-30. PubMed ID: 17852710
[TBL] [Abstract][Full Text] [Related]
11. The role of clofarabine in acute myeloid leukemia.
Ghanem H; Kantarjian H; Ohanian M; Jabbour E
Leuk Lymphoma; 2013 Apr; 54(4):688-98. PubMed ID: 22957815
[TBL] [Abstract][Full Text] [Related]
12. Assessing signaling pathways associated with in vitro resistance to cytotoxic agents in AML.
Rosen DB; Cordeiro JA; Cohen A; Lacayo N; Hogge D; Hawtin RE; Cesano A
Leuk Res; 2012 Jul; 36(7):900-4. PubMed ID: 22521550
[TBL] [Abstract][Full Text] [Related]
13. Clofarabine: emerging role in leukemias.
Sampat K; Kantarjian H; Borthakur G
Expert Opin Investig Drugs; 2009 Oct; 18(10):1559-64. PubMed ID: 19715446
[TBL] [Abstract][Full Text] [Related]
14. Valproic acid synergistically enhances the cytotoxicity of clofarabine in pediatric acute myeloid leukemia cells.
Xie C; Edwards H; Lograsso SB; Buck SA; Matherly LH; Taub JW; Ge Y
Pediatr Blood Cancer; 2012 Dec; 59(7):1245-51. PubMed ID: 22488775
[TBL] [Abstract][Full Text] [Related]
15. Novel and emerging drugs for acute myeloid leukemia: pharmacology and therapeutic activity.
Robak T; Szmigielska-Kapłon A; Pluta A; Grzybowska-Izydorczyk O; Wolska A; Czemerska M; Wierzbowska A
Curr Med Chem; 2011; 18(5):638-66. PubMed ID: 21182488
[TBL] [Abstract][Full Text] [Related]
16. A comparison of azacitidine and decitabine activities in acute myeloid leukemia cell lines.
Hollenbach PW; Nguyen AN; Brady H; Williams M; Ning Y; Richard N; Krushel L; Aukerman SL; Heise C; MacBeth KJ
PLoS One; 2010 Feb; 5(2):e9001. PubMed ID: 20126405
[TBL] [Abstract][Full Text] [Related]
17. Biochemical modulation of cytarabine triphosphate by clofarabine.
Cooper T; Ayres M; Nowak B; Gandhi V
Cancer Chemother Pharmacol; 2005 Apr; 55(4):361-368. PubMed ID: 15723262
[TBL] [Abstract][Full Text] [Related]
18. Clofarabine as a novel nucleoside analogue approved to treat patients with haematological malignancies: mechanism of action and clinical activity.
Lech-Maranda E; Korycka A; Robak T
Mini Rev Med Chem; 2009 Jun; 9(7):805-12. PubMed ID: 19519505
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the cytotoxicity of cladribine and clofarabine when combined with fludarabine and busulfan in AML cells: Enhancement of cytotoxicity with epigenetic modulators.
Valdez BC; Li Y; Murray D; Ji J; Liu Y; Popat U; Champlin RE; Andersson BS
Exp Hematol; 2015 Jun; 43(6):448-61.e2. PubMed ID: 25704054
[TBL] [Abstract][Full Text] [Related]
20. Clofarabine targets the large subunit (α) of human ribonucleotide reductase in live cells by assembly into persistent hexamers.
Aye Y; Brignole EJ; Long MJ; Chittuluru J; Drennan CL; Asturias FJ; Stubbe J
Chem Biol; 2012 Jul; 19(7):799-805. PubMed ID: 22840768
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
